

CCSS Statistical Center Report

CCSS Investigator Meeting, June 14, 2021

Wendy Leisenring, Sc.D.

CCSS

Childhood Cancer
Survivor Study



St. Jude Children's
Research Hospital

An NCI-funded Resource

- Overview and Team Members
- Core Activity Updates
- Priorities for the next 5 years

- **Data Management**
 - Close collaboration with Coordinating Center (weekly meetings)
 - Cleaning data
 - Generating analytic data sets
 - Linkage with external data sources
- **Concept Proposal and Grant Development**
 - Design and write in collaboration with investigators
- **Statistical Analyses**
 - Collaborate on analyses via regular virtual meetings with investigators

Staffing

CCSS



Wendy Leisenring, ScD
Lead CCSS Biostatistician
30% Wendy
2 FTE over 3 MS

Analysts

Pam Goodman
Kayla Stratton
Jillian Whitton



Yutaka Yasui, PhD
20% Yutaka

Qi Liu
Yan Chen
Weiyu Qiu
Cindy Im
Nan Li



Kumar Srivastava, PhD
10% Kumar

Wei Liu
Mingjuan Wang
Mengqi Xing
Sedigheh Mirzaei

Survey Data

- Survey Response data through FU6 data
- Subsequent Neoplasms reported and confirmed through FU6
- Chronic Health Conditions coded through FU5

Mortality

- Vital status and cause of death through 2017 (National Death Index linkage)

Treatment for Primary Cancer (up to 5 years post dx)

- Chemotherapy abstracted from medical records, cumulative dose
- Radiation Dosimetry to body regions and organs (MD Anderson)
- Surgery Operative notes coded to ICD9

CCSS dbGaP Data Repository Update:

- Phenotype data set available now on dbGaP
 - All 25,665 survivors and 5,501 siblings
 - Demographic, Cancer characteristics, Treatment exposures (chemotherapy, RT body regions)
 - Outcomes: Mortality, SMNs, Chronic Condition Grades /ages
 - Within dbGaP, phenotype data will be linkable with subset of survivors with genetic data available (N = 5,912) with appropriate approvals.

St Jude Cloud

- CCSS Expansion cohort subjects with Whole Genome Sequencing data (N=2,641)
- CCSS Phenotype data similar to that described above for dbGaP has been uploaded
- Online tools at St Jude Cloud available (<http://survivorship.stjude.cloud/>)

- **Completed: Society for Assisted Reproductive Technology (SART)**
 - Linkage accomplished between CCSS and SART data
 - Obtained data for CCSS survivors who received ART
 - Analyses completed and manuscript draft written
- **Ongoing: Virtual Pooled Registry (VPR)**
 - State by state linkage of cancer registries to CCSS survivors
 - 30 participating registries – we have data from 22 so far
 - Analyses initiated to evaluate the utility of this process for identifying subsequent neoplasms
- **Initiating: Medicaid Data**
 - Approved concept, grant submitted
 - CCSS participants alive and aged 18-64 years as of Jan 1, 2010
 - 2009-2016 Medicaid claims data

Manuscript and Analyses Volume Supported by the CCSS Statistical Center

CCSS

January 1, 2017-Present*:	
Published Manuscripts:	96
Currently Submitted Manuscripts:	7
Manuscripts in Preparation:	25
Analyses Ongoing/Data sent:	45

* Current grant funding period

Concepts Approved, waiting for specific data:	
Approved Concepts in Queue Waiting for Analyst:	4
Approved Concepts in Queue Waiting for Linkage/Data:	3
Concept Proposals Under Development:	10+

Methodological:

- **Drop-out concerns:** Bias due to non-participation / Loss to follow-up
- **(One) solution:** We have advocated using inverse probability weighting (IPW) to adjust all analyses.
- **Participation Weights:** We have generated weights to ameliorate bias due to non-participation / drop-out across all surveys.
- **Challenge:** Have applied weights to recent analyses
 - Overly complicates some analyses and can be time consuming to implement
 - Still advocating, but thus far, bias is minimal. Be flexible and vigilant.

Priorities: Next 5 Years

Analyses: Maintain productivity and quality on analytic projects

Data: The Coordinating Center's "Next 5 years" list items will nearly all provide data to us to clean, incorporate and analyze.

Study Designs: Support ancillary studies, including in-home frailty assessment, neurocognitive assessments, health services research initiatives, and intervention trials with innovative and rigorous study designs and analyses.

Planning for Cohort Expansion: With others, we will develop a plan for cohort expansion in the future, aimed at studying late effects of novel therapies (immunotherapy, targeted/biologic, proton beam radiation)